SERTOLI , Mario Roberto

No description

No description

A controlled study was mounted to assess the possible benefit of a single phlebo administration of 600 mg lincomycin 1 hr prior to colon surgery, in addition to the erythromycin + neomycin combination proposed by Nichols, as a means of constituting a further pharmacological barrier to the spread of anaerobic bacteria. The study currently...

No description

No description

No description

No description

No description

The clinical features of 10 cases of primary neuroendocrine carcinoma of the skin (Merker cell tumor) are reported. This cancer arises in the dermis and subcutaneous tissues of elderly individuals. Natural history is characterized by local recurrences (30\%), regional lymph node metastases (65\%) and distant metastases (40\%). Surgery is...

Abstract BACKGROUND: Angiosarcoma (AS) accounts for 1 to 2% of all soft tissue sarcoma. Both primary and secondary AS may occur, the latter being reported in the upper extremity with lymphedema after extended radical mastectomy for breast cancer (postmastectomy AS) or following radiotherapy of the breast, the thoracic wall, or other sites...

Background: Standard methods to prevent chemotherapy-induced early menopause in young, breast cancer patients are unavailable to date. Preclinical data has suggested that luteinising hormone-releasing hormone (LH-RH) analogs given during treatment can decrease the gonado-toxicity induced by chemotherapy. This phase II study aimed to assess the...

No description

No description

No description

No description

No description

In a phase-I-study recombinant interleukin-2 (rIL-2) in a dose from 0.01 to 0.3 mg/m2/day for 7 to 14 days was infused intraperitoneally. Side effects were fever and fluid retention. 2 patients showed a bacterial peritonitis after paracentesis. The investigations showed that the intraperitoneal (i.p.) administration of interleukin-2 activates...

No description

No description

No description

The addition of Rituximab (anti-CD20 monoclonal antibody) to chemotherapy has dramatically increased survival of non-Hodgkin's lymphoma (NHL) patients. However, in view of the intrinsic immunosuppressive effect of this drug, new questions are emerging in clinical practice. Among these, the assessment and proper interpretation of HBV serological...

Purpose: To assess the clinical and biological activity of the association of bevacizumab and fotemustine as first-line treatment in advanced melanoma patients. Experimental Design: Previously untreated, metastatic melanoma patients (n = 20) received bevacizumab (at 15 mg/kg every 3 weeks) and fotemustine (100 mg/m(2) by intravenous...

Background. To determine whether a dose-dense regimen improves outcome in early breast cancer patients, we compared outcomes with the same fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapeutic regimen administered every 3 weeks (FEC21) or administered every 2 weeks (FEC14 including support with filgrastim, a granulocyte...